In gliomas, for instance, KEAP1 expression may be reduced in the infiltrative tumor edge compared with the tumor core, influencing ferroptosis resistance and the effectiveness of ferroptosis‐targeted therapies in these regions. The gene discussed is KEAP1; the disease is central nervous system cancer.